MNMD

MNMD

USD

Mind Medicine (MindMed) Inc. Common Shares

$12.000-0.100 (-0.826%)

السعر في الوقت الحقيقي

Healthcare
التكنولوجيا الحيوية
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$12.100

الأعلى

$12.530

الأدنى

$11.880

الحجم

2.12M

أساسيات الشركة

القيمة السوقية

1.2B

الصناعة

التكنولوجيا الحيوية

البلد

United States

إحصاءات التداول

متوسط الحجم

1.69M

البورصة

NMS

العملة

USD

نطاق 52 أسبوعاً

الأدنى $4.7الحالي $12.000الأعلى $14.43

أخبار ذات صلة

BusinessWire

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the closing

عرض المزيد
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
BusinessWire

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing

عرض المزيد
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
BusinessWire

MindMed Announces New Employee Inducement Grant

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance

عرض المزيد
MindMed Announces New Employee Inducement Grant
Analyst Upgrades

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Needham starts MindMed at Buy with a $28 target, citing strong Phase 3 prospects for MM120 in anxiety and depression and solid cash position.

عرض المزيد
Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.